Abstract
Prostate cancer is often a complex disease and one in which many aspects of the disease and the affected patient must be taken into consideration before decisions about diagnostic work-up, treatments, follow-up, etc. can be made. The current chapter reflects the current recommendations of the European Prostate Cancer Guideline Group made on the basis of criteria of evidence-based medicine after extensive review of the literature available up to December 2005.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Krege S, Souchon R, Schmoll HJ; for the German Testicular Cancer Study Group (2001) Interdisciplinary consensus on diagnosis and treatment of testicular germ cell tumours: result of an update conference on evidence-based medicine. Eur Urol 40:372–391
Schmoll HJ, Souchon R, Krege S, et al (2004) European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 15:1377–1399
Schrader AJ, Ohlmann CH, Rossmanith S, Hofmann R, Heidenreich A (2006) Impact of evidence-based guidelines on testis cancer management. Cancer 106:313–319
Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid HP, van Poppel H, Wolff J, Zattoni F (2005) EAU guidelines on prostate cancer. Eur Urol 48:546–551
US Department of Health and Human services (1992) Public Health Service, Agency for Health Care Policy and Research 1992, pp 115–127. http://www.ahcpr.gov. Cited 29 Sept 2006
Sobin LH, Wittekind C (eds) (2002) TNM classification of malignant tumours, 6th edn. Wiley-Liss, New York
Gleason DF, Mellinger GT (1974) Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111:58–64
Oliver SE, May MT, Gunnell D (2001) International trends in prostate-cancer mortality in the ‘PSA-ERA’. Int J Cancer 92:893–898
Helgesen F, Holmberg L, Johansson JE, Bergstrom R, Adami HO (1996) Trends in prostate cancer survival in Sweden, 1960 through 1988, evidence of increasing diagnosis of non-lethal tumours. J Natl Cancer Inst 88:1216–1221
Post PN, Kil PJ, Coebergh JW (1999) Trends in survival of prostate cancer in southeastern Netherlands 1971–1989. Int J Cancer 81:551–554
Bartsch G, Horninger W, Klocker H, et al (2001) Prostate cancer mortality after introduction of prostatespecific antigen mass screening in the Federal State of Tyrol, Austria. Urology 58:417–424
Lu-Yao G, Albertsen PC, Stamford JL, Stukel TA, Walker-Corkery ES, Barry MJ (2002) Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 325:740
Schmid HP, Riesen W, Prikler L (2004) Update on screening for prostate cancer with prostate-specific antigen. Crit Rev Oncol Hematol 50:71–78
Lodding P, Aus G, Bergdahl S, Frosing R, Lilja H, Pihl CG, Hugosson J (1998) Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng/ml. Prostate specific antigen. J Urol 159:899–903
Horninger W, Reissigl A, Rogatsch H, Volgger H, Studen M, Klocker H, Bartsch G (2000) Prostate cancer screening in the Tyrol, Austria: experience and results. Eur J Cancer 36:1322–1355
Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level <or =4.0 ng per milliliter. N Engl J Med 350:2239–2246
Stamey TA (1995) Making the most out of six systemic sextant biopsies. Urology 45:2–12
Aus G, Bergdahl S, Hugosson J, Lodding P, Pihl CG, Pileblad E (2001) Outcome of laterally directed sextant biopsies of the prostate in screened males aged 50–66 years. Implications for sampling order. Eur Urol 139:655–660
Eskew LA, Bare RL, McCullough DL (1997) Systemic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 157:199–202
Morote J, Lopez M, Encabo G, de Torres I (1999) Value of routine transition zone biopsies in patients undergoing ultrasound-guided sextant biopsies for the first time. Eur Urol 35:294–297
Terris MK, Pham TQ, Issa MM, Kabalin JN (1997) Routine transition zone and seminal vesicle biopsies in all patients undergoing transrectal ultrasound guided prostate biopsies are not indicated. J Urol 157:204–206
Applewhite JC, Matlaga BR, McCullough DL (2002) Results of the 5 region prostate biopsy method: the repeat biopsy population. J Urol 168:500–503
Roehrborn CG, Pickers GJ, Sanders JS (1996) Diagnostic yield of repeated transrectal ultrasound-guided biopsies stratified by specific histopathologic diagnosis and prostate specific antigen levels. Urology 47:347–352
Djavan B, Ravery V, Zlotta A, Dobronski P, Dobrovits M, Fakhari M, Seitz C, Susani M, Borkowski A, Boccon-Gibod L, Schulman CC, Marberger M (2001) Prospective evaluation of prostate cancer detected on biopsies 1,2,3 and 4; when should we stop? J Urol 166:1679–1683
Zlotta AR, Raviv G, Schulman CC (1996) Clinical prognostic criteria for later diagnosis of prostate carcinoma patients with initial isolated prostatic intraepithelial neoplasia. Eur Urol 30:249–255
Haggman MJ, Macoska JA, Wojno KJ, Oesterling JE (1997) The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues. J Urol 158:12–22
Oyen RH (1996) Imaging modalities in diagnosis and staging of carcinoma of the prostate. In: Brady LW, Heilmann HP, Petrovich Z, Baert L, Brady LW, Skinner DG (eds) Carcinoma of the Prostate. Innovations and Management. Springer-Verlag, Berlin Heidelberg New York, pp 65–96
Rorvik J, Halvorsen OJ, Servoll E, Haukaas S (1994) Transrectal ultrasonography to assess local extent of prostatic cancer before radical prostatectomy. Br J Urol 73:65–69
Smith JA Jr, Scardino PT, Resnick MI, Hernandez AD, Rose SC, Egger MJ (1997) Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective multi-institutional trial. J Urol 157:902–906
Liebross RH, Pollack A, Lankford SP, Zagars GK, von Eshenbach AC, Geara FB (1999) Transrectal ultrasound for staging prostate carcinoma prior to radiation therapy: an evaluation based on disease outcome. Cancer 85:1577–1585
Heenan SD (2004) Magnetic resonance imaging in prostate cancer. Prostate Cancer Prostatic Dis 7:282–288
Heidenreich A, Varga Z, Von Knobloch R (2002) Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 167:1681–1686
Bader P, Burkhard FC, Markwalder R, Studer UE (2002) Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 168:514–518
Golimbu M, Morales P, Al-Askari S, Schulman Y (1981) CAT scanning in staging of prostatic cancer. Urology 18:305–508
Hricak H, Dooms GC, Jeffrey RB, Avallone A, Jacobs D, Benton WK, Narayan P, Tanagho EA (1987) Prostatic carcinoma: staging by clinical assessment, CT and MR imaging. Radiology 162:331–336
Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van der Kaa CH, de la Rosette J, Weissleder R (2003) Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348:2491–2499
Buell U, Kleinhans E, Zorn-Bopp E, Reuschel W, Muenzing W, Moser EA, Seiderer M (1982) A comparison of bone imaging with Tc-99m DPD and Tc-99m MDP: concise communication. J Nucl Med 23:214–217
Soloway MS, Hardemann SW, Hickey D, Raymond J, Todd B, Soloway S, Moinuddin M (1988) Stratification of patients with metastatic prostate cancer based on the extent of disease on initial bone scan. Cancer 61:195–202
Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, Chisholm GD, Moskovitz B, Livne PM, Warner J (1994) Results of conservative management of clinically localized prostate cancer. N Engl J Med 330:242–248
Middleton RG, Thompson IM, Austenfeld MS, Cooner WH, Correa RJ, Gibbons RP, Miller HC, Oesterling JE, Resnick MI, Smalley SR, Wasson JH (1995) Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. The American Urological Association. J Urol 154:2144–2148
Thompson IM (1994) Observation alone in the management of localized prostate cancer: the natural history of untreated disease. Urology 43:41–46
Schellhammer PF (1994) Contemporary expectant therapy series: a viewpoint. Urol Symp 44:47–52
Steinberg GD, Bales GT, Brendler CB (1998) An analysis of watchful waiting for clinically localized prostate cancer. J Urol 159:1431–1436
Adolfsson J, Steineck G, Whitmore WF Jr (1993) Recent results of management of palpable clinically localized prostate cancer. Cancer 72:310–322
Albertsen PC, Hanley JA, Gleason DF, Barry MJ (1998) Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280:975–980
Albertsen P, Hanley JA, Murphy-Setzko M (1999) Statistical considerations when assessing outcomes following treatment for prostate cancer. J Urol 162:439–444
Klotz L (2004) Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer. J Urol 172:S48–S50
Klotz L (2005) Active surveillance for good risk prostate cancer: rationale, method, and results. Can J Urol 12(Suppl 2):21–24
Medical Research Council Prostate Cancer Working Party Investigators Group (1997) Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 79:235–246
Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K (2004) Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: result from the second analysis of the early prostate cancer programme at median follow-up of 5.4 years. J Urol 172:1865–1870
Studer UE, Hauri D, Hanselmann S, Chollet D, Leosinger HJ, Gasser T, Senn E, Trinkler FB, Tscholl RM, Thalmann GN, Dietrich D (2004) Immediate versus delayed hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88. J Clin Oncol 22:4109–4118
Walsh PC (1997) Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. J Urol 158:1623–1624
Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Haggman M, Andersson SO, Spangberg A, Busch C, Nordling S, Palmgren J, Adami HO, Johansson JE, Norlen BJ, for the Scandinavia Prostatic Cancer Group Study Number 4 (2002) A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 347:781–789
Huland H (1997) Treatment of localized disease: treatment of clinically localized prostate cancer (T1/T2). In: Murphy G, Denis L, Chatelain C, Griffiths K, Khoury S, Cockett AT (eds) Proceedings of the First International Consultation on Prostate Cancer. Scientific Communication International, Jersey, pp 227–257
Corral DA, Bahnson RR (1994) Survival of men with clinically localized prostate cancer detected in the eighth decade of life. J Urol 151:1326–1329
Lowe BA, Listrom MB (1988) Incidental carcinoma of the prostate: an analysis of the predictors of progression. J Urol 140:1340–1344
Elgamal AA, Van Poppel HP, Van de Voorde WM, Van Dorpe JA, Oyen RH, Baert LV (1997) Impalpable invisible stage T1c prostate cancer: characteristics and clinical relevance in 100 radical prostatectomy specimens-a different view. J Urol 157:244–250
Oesterling JE, Suman VJ, Zincke H, Bostwick DG (1993) PSA-detected (clinical stage T1c or B0) prostate cancer. Pathologically significant tumours. Urol Clin North Am 20:687–693
Epstein JI, Walsh PC, Brendler CB (1994) Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumours found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C). J Urol 152:1721–1729
Schroder FH, Van den Ouden D, Davidson P (1992) The role of surgery in the cure of prostatic carcinoma. Eur Urol Update Series 1:18–23
Gibbons RP (1988) Total prostatectomy for clinically localized prostatic cancer: long-term surgical results and current morbidity. NCI Monogr 7:123–126
Pound CR, Partin AW, Epstein JI, Walsh PC (1997) Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 24:395–406
Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 360:103–108
Epstein JI, Chan DW, Sokoll LJ, Walsh PC, Cox JL, Rittenhouse H, Wolfert R, Carter HB (1998) Non-palpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 160:2407–2411
Van den Ouden D, Hop W, Schroder FH (1998) Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 160:1392–1397
Van Poppel H, Goethuys H, Callewaert P, Vanuytsel L, Van de Voorde WM, Baert L (2000) Radical prostatectomy can provide a cure for well-selected clinical stage T3 prostate cancer. Eur Urol 38:372–379
Heidenreich A, Ohlmann CH, Özgür E, Btaun M, Engelmann UH (2005) Extended retropubic radical prostatectomy in clinical stage T3 prostate cancer: significant reduction of positive surgical margins in a case control study. Eur Urol Suppl 4:8
Ghavamian R, Bergstralh EJ, Blute ML, Slezak J, Zincke H (1999) Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J Urol 161:1223–1227
Aus G, Abrahamsson PA, Ahlgren G, Hugosson J, Lundberg S, Schain M, Schelin S, Pedersen K (2002) Three-month neoadjuvant hormonal therapy before radical prostatectomy; a 7-year follow-up of a randomized controlled trial. BJU Int 90:561–566
Soloway MS, Pareek K, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, Puras-Baez A (2002) Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxM0 prostate cancer: 5-year results. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 167:112–116
Schulman CC, Debruyne FM, Forster G, Selvaggi FP, Zlotta AR, Witjes WP (2000) 4-year followup results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-T3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol 38:706–713
Van Poppel H, Goethuys H, De Ridder D, Verleyen P, Ackaert K, Werbrouck P, De Coster M, Baert L, the Members of the BUOS (2001) Neoadjuvant therapy before radical prostatectomy: impact on progression free survival. Uro-Oncology 1:301–307
Gleave ME, Goldenbergh L, Chin JL, Warnes J, Saad F, Klotz L, Jewett M, Kassabian V, Chetner M, Dupont C (2003) Randomized comparative study of 3 vs 8 months of neoadjuvant hormonal therapy prior to radical prostatectomy: 3 year PSA recurrence rates. J Urol 169(Suppl):179 Abstr 690
Hanks GE, Hanlon AL, Schultheiss TE, Pinover WH, Movsas B, Epstein BE, Hunt MA (1998) Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 41:501–510
Pollack A, Zagars GK, Smith LG, Lee JJ, von Eschenbach AC, Antolak JA, Starkschall G, Rosen I (2000) Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 18:3904–3911
Zietman AL, DeSilvio M, Slater JD, et al (2004) A randomized trial comparing conventional dose (70.2 GyE) and high-dose (79.2 GyE) conformal radiation in early stage adenocarcinoma of the prostate: results of an interim analysis of PROG 95-09. Int J Radiat Oncol Biol Phys 60:S131 (Abstr 4)
MRC Radiotherapy Working Party (1998) RT01. A randomized trial of high dose therapy in localized cancer of the prostate using conformal radiotherapy techniques. Clinical protocol. January
Beckendorf V, Guérif S, Le Prise E, Cosset JM, Lefloch O, Chauvet B, Salem N, Chapet O, Bourdin S, Bachaud JM, Maingon P, Lagrange JL, Malissard L, Simon JM, Pommier P, Hay MH, Dubray B, Luporsi E, Bey P (2004) The GETUG 70 Gy vs 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. Int J Radiat Oncol Biol Phys 60:1056–1065
Bolla M (1999) Three Dimensional Conformal Radiotherapy alone vs Three Dimensional Conformal Therapy plus adjuvant hormonal therapy in localized T1b-c, T2a, N0, M0 prostatic carcinoma. A Phase III Randomized Study. EORTC protocol 22991. EORTC Data Centre, Brussels
D’Amico A, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW (2004) 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer; a randomized controlled trial. JAMA 292:821–827
Roach M, Marquez C, Yuo H, Narayan P, Coleman L, Nseyo UO, Navvab Z, Carroll PR (1993) Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 28:33–37
Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, Amols H, Venkatraman ES, Leibel SA (2002) High dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53:1111–1116
Ash D, Flynn A, Batterman J, de Reijke T, Lavagnini P, et al (2000) ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 57:315–321
Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E (2002) Biochemical outcome for hormone naive patients with Gleason score 3+4 versus 4+3 prostate cancer undergoing permanent prostate brachytherapy. Urology 60:98–103
Potters L, Cha C, Ashley R, Barbaris H, Leibel S (1998) Is pelvic radiation necessary in patients undergoing prostate brachytherapy? Int J Radiat Oncol Biol Phys 42:300 (Abstr 2146)
Lee LN, Stock RG, Stone NN (2002) Role of neoadjuvant hormonal therapy in the management of intermediate-to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 52:444–452
Galalae RM, Kovacs G, Schultze J, Loch T, Rzehak P, Wilhelm R, Bertermann H, Buschbeck B, Kohr P, Kimmig B (2002) Long term outcome after elective irradiation on the pelvic lymphatics and local dose escalation using high dose rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 52:81–90
Bolla M, Van Poppel H, Van Cangh PJ et al (2002) Acute and late toxicity of post operative external irradiation in pT3N0 prostate cancer patients treated within EORTC trial 22911. Int J Rad Oncol Biol Phys; 54(Suppl 2): S62 Abstr 103
Huggins C, Hodges CV (1941) Studies on prostate cancer I. The effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293–297
Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon D (2001) Phase III radiation therapy oncology group (RTOG) trial 86-10 adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50:1243–1252
Reference deleted in proof
Lawton CA, Winter K, Byhardt R, Sause WT, Hanks GE, Russell AH, Rotman M, Porter A, McGowan DG, DelRowe JD, Pilepich MV (1997) Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Int J Radiat Oncol Biol Phys 38:931–939
Hanks GE, Pajak TF, Porter A, et al (2003) RTOG 92-02: phase III trial of of long term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. J Clin Oncol 21:3972–3978
Huggins C, Stevens RE Jr, Hodges CV (1941) Studies on prostate cancer. II. The effect of castration on advanced carcinoma of the prostate gland. Arch Surg 43:209–223
Jordan WP Jr, Blackard CE, Byar DP (1977) Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma. South Med J 70:1411–1413
Byar DP (1973) Proceedings: the Veterans Administration Co-operative Urological Research Group studies of cancer of the prostate. Cancer 32:1126–1130
Scherr DS, Pitts WR Jr (2003) The non-steroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer. J Urol 170:1703–1708
Oh WK (2002) The evolving role of estrogen therapy in prostate cancer. Clin Prostate Cancer 1:81–89
Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, Wilt TJ (2000) Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 132:566–577
McLeod DG (2003) Hormonal therapy: historical perspective to future directions. Urology 61(Suppl 2A):3–7
Oefelein MG, Resnick MI (2003) Effective testosterone suppression for patients with prostate cancer: is there a best castration? Urology 62:207–213
Bubley GJ (2001) Is the flare phenomenon clinically significant? Urology 58(Suppl 2A):5–9
FDA/ CDER (2003) FDA approves new drug for advanced prostate cancer. 25 November 2003
Moffat LE (1990) Comparison of Zoladex, diethylstilboestrol and cyproterone acetate treatment in advanced prostate cancer. Eur Urol 18(Suppl 3):26–27
Schröder FH, Whelan P, de Reijke TM, Kurth KH, Pavone Macaluso M, Mattelaer J, van Velthoven RF, Debois M, Collette L((2004) Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the ‘uropean Organization for Research and Treatment of Cancer’ (EORTC) Protocol 30892. Eur Urol 45:457–46
Thorpe SC, Azmatullah S, Fellows GJ, Gingell JC, O’Boyle PJ (1996) A prospective, randomized study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma. Eur Urol 29:47–54
McLeod DG (1997) Tolerability of non-steroidal antiandrogens in the treatment of advanced prostate cancer. Oncologist 2:18–27
Narayana AS, Loening SA, Culp DA (1981) Flutamide in the treatment of metastatic carcinoma of the prostate. Br J Urol 53:152–153
Sogani PC, Vagaiwala MR, Whitmore WF Jr (1984) Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy. Cancer 54:744–750
Lundgren R (1987) Flutamide as primary treatment for metastatic prostatic cancer. Br J Urol 59:156–158
Delaere KP, Van Thillo EL (1991) Flutamide monotherapy as primary treatment in advanced prostatic carcinoma. Semin Oncol 18(Suppl 6):13–18
Pavone Macaluso M (1994) Flutamide monotherapy versus combined androgen blockade in advanced prostate cancer. Interim report of an Italian multicentre, randomized study. SIU 23rd Congress 354A
Boccon-Gibod L, Fournier G, Bottet P, Marechal JM, Guiter J, Rischman P, Hubert J, Soret JY, Mangin P, Mallo C, Fraysse CE (1997) Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. Eur Urol 32:391–395
Tyrrell CJ, Denis L, Newling DWW, Soloway M, Channer K, Cockshott ID (1998) Casodex 10–200 mg daily, used as monotherapy for the patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group. Eur Urol 33:39–53
Kolvenbag GJ, Nash A (1999) Bicalutamide dosages used in the treatment of prostate cancer. Prostate 39:47–53
Fourcade RO, Chatelain C, Poterre M, et al (1998) An open multicentre randomized study to compare the effect and safety of ‘Casodex’ (bicalutamide) 150 mg monotherapy with castration plus nilutamide in metastatic prostate cancer. Eur Urol 33(Suppl 1):88, 349A
Boccardo F, Barichello M, Battaglia M, Carmignani G, Comeri G, Ferraris V, Lilliu S, Montefiore F, Portoghese F, Cortellini P, Rigatti P, Usai E, Rubagotti A (2002) Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. Eur Urol 42:481–490
Reference deleted in proof
Seidenfeld J, Samson DJ, Aronson N, Albertson PC, Bayoumi AM, Bennett C, Brown A, Garber A, Gere M, Hasselblad V, Wilt T, Ziegler K (1999) Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evidence Report/Technology Assessment No. 4. AHCPR Publication No. 99-E0012. Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services, Rockville
Prostate Cancer Trialists’ Collaborative Group (2000) Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. Lancet 355:1491–1498
Schmitt B, Bennett CL, Seidenfeld J, Samson DJ, Wilt TJ (2000) Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst Rev 2:D001526
Schmitt B, Wilt TJ, Schellhammer PF, De Masi V, Sartor O, Crawford ED, Bennett CL (2001) Combined androgen blockade with non-steroidal antiandrogens for advanced prostate cancer: a systematic review. Urology 57:727–732
Samson DJ, Seidenfeld J, Schmitt B, Hasselblad V, Albertsen PC, Bennett CL, Wilt TJ, Aronson N (2002) Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 95:361–376
Fleshner NE, Trachtenberg J (1995) Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side-effects. J Urol 154:1645–1646
Fleshner NE, Fair WR (1996) Anti-androgenic effects of combination finasteride plus flutamide in patients with prostatic carcinoma. Br J Urol 78:907–910
Ornstein DK, Rao GS, Johnson B, Charlton ET, Andriole GL (1996) Combined finasteride and flutamide therapy in men with advanced prostate cancer. Urology 48:901–905
Brufsky A, Fontaine-Rothe P, Berlane K, Rieker P, Jiroutek M, Kaplan I, Kaufman D, Kantoff P (1997) Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology 49:913–920
Kirby R, Robertson C, Turkes A, Griffiths K, Denis LJ, Boyle P, Altwein J, Schröder F((1999) Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. International Prostate Health Council (IPHC) Trial Study Group. Prostate 40:105–114
Oh WK, Manola J, Bittman L, Brufsky A, Kaplan ID, Smith MR, Kaufman DS, Kantoff PW (2003) Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up. Urology 62:99–104
Pether M, Goldenberg SL (2004) Intermittent androgen suppression. BJU Int 93:258–261
Bayoumi AM, Brown AD, Garber AM (2000) Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst 92:1731–1739
Reference deleted in proof
Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D (1999) Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341:1781–1788
Nair B, Wilt T, MacDonald R, Rutks I (2002) Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev 1:CD003506
Loblaw DA, Mendelson DS, Talcott JA, Virgo KS, Somerfield MR, Ben-Josef E, Middleton R, Porterfield H, Sharp SA, Smith TJ, Taplin ME, Vogelzang NJ, Wade JL Jr, Bennett CL, Scher HI (2004) American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 22:1–15
Ryan CJ, Small EJ (2003) Role of secondary hormonal therapy in the management of recurrent disease. Urology 62(Suppl 6B):87–94
Kelly WK, Scher HI (1993) Prostate specific antigen decline after antiandrogen withdrawal syndrome. J Urol 149:607–609
Scher HI, Kelly WK (1993) Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11:1566–1572
Small EJ, Carroll PR (1994) Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 43:408–410
Dawson NA, McLeod DG (1995) Dramatic prostate specific antigen decline in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. J Urol 153:1946–1947
Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable P, Torti FM, Kaplan E, Vogelzang N (2004) Antiandrogen withdrawal alone or in combination with ketokonazole in androgenindependent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 22:1025–1033
Ohlmann C, Cordia I, Schilling I, Engelmann U, Heidenreich A (2005) Ketokonazol/hydrocortisone versus estramustine phosphate in the management of PSA progression following primary androgen deprivation for metastatic prostate cancer. Eur Urol Suppl 4:249
Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin M, Burch PA, Berry D, Mounpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520
Tannock IF, de Wit R, Berry WR, et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512
Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14:1756–1764
Kanthoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ (1999) Hydrocortisine with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 Study. J Clin Oncol 17:2506–2513
Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, Sathyanarayana JR, Yakemchuk VN, Thomas GM, Erlich LE, Crook J, Gulenchyn KY, Hong KE, Wesolowski C, Yardlye J (1993) Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 25:805–813
Palmedo H, Manka-Waluch A, Albers P, Schmidt-Wolf IG, Reinhard D, Ezzidin S, Joe A, Roedel R, Fimmers R, Knapp FF Jr, Guhlke S, Biersack HJ (2003) Repeated bone-targeted therapy for hormonerefractory prostate carcinoma: randomized phase II trial with the new high-energy radiopharmaceutical rhenium-188 hydroxyethylidene-diphosphonate. J Clin Oncol 21:2869–2875
Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goad JA, Chen B (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458–1468
Heidenreich A, Hofmann R, Engelmann UH (2001) The use of bisphosphonates for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol 165:136–140
Heidenreich A, Elert A, Hofmann R (2002) Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis 5:231–235
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Heidenreich, A. (2007). Guidelines and Counselling for Treatment Options in the Management of Prostate Cancer. In: Ramon, J., Denis, L.J. (eds) Prostate Cancer. Recent Results in Cancer Research, vol 175. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-40901-4_9
Download citation
DOI: https://doi.org/10.1007/978-3-540-40901-4_9
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-40897-0
Online ISBN: 978-3-540-40901-4
eBook Packages: MedicineMedicine (R0)